Why Is Acurx Pharmaceuticals Stock Up Over 105% Today?

Group 1 - Acurx Pharmaceuticals Inc shares are experiencing significant gains, with a reported increase of 105.17% to $5.95, attributed to investor reactions to recent developments regarding its antibiotic candidate, ibezapolstat [1][5] - The company is initiating a new clinical trial program for ibezapolstat targeting patients with recurrent C. difficile infection (rCDI) and plans to advance the drug into Phase 3 international studies for the broader CDI population, pending funding [2] - Ibezapolstat has received FDA Fast Track status and is positioned to potentially be the first single agent to treat CDI and prevent recurrent infections, indicating a significant shift in treatment approaches [3] Group 2 - The Relative Strength Index (RSI) for Acurx Pharmaceuticals has surged into the high 80s, indicating that the stock has entered overbought territory following a strong momentum move [4]